Michael H. Tardugno
President and Chief Executive Officer
Mr. Tardugno’s career has been exclusively focused in healthcare with 30 years of experience in the pharmaceutical and medical device industries. Mr. Tardugno was appointed President and Chief Executive Officer of the Company on January 3, 2007 and was elected to the Board of Directors on January 22, 2007. Prior to joining the company, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies Inc., a subsidiary of Mylan Laboratories, a transdermal drug company. He was a founding member of management of Songbird Hearing, Inc., a privately held start-up, and held the positions of Senior Vice President of Technical Operations at Bristol-Myers Squibb and Senior Vice President of Technology Development and Manufacturing for Bausch & Lomb. Mr. Tardugno began his career in 1977 with Abbott Laboratories where he held positions in pharmaceutical operations. Mr. Tardugno holds a B.S. in Biology from St. Bonaventure University and completed the Harvard Business School executive program.
Nicholas Borys M.D.
Vice President and Chief Medical Officer
Nicholas Borys, M.D. joined Celsion in October 2007 as Vice President and Chief Medical Officer. In this position Dr. Borys manages the clinical development program for Celsion. Dr. Borys, who was most recently Chief Medical Officer at Molecular Insight Pharmaceuticals, Inc., has accumulated extensive experience in all phases of pharmaceutical development with a focus in oncology while holding increasingly senior positions at Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc. Dr. Borys attended Rutgers University and holds an M.D. Degree from American University of the Caribbean.
Jeffrey W. Church
Senior Vice President, Chief Financial Officer and Corporate Secretary
Jeffrey W. Church was appointed Senior Vice President and Chief Financial Officer in July 2013. Mr. Church resumed the role of Chief Financial Officer, a position he held prior to his promotion to Senior Vice President in July 2011. In this position he will retain responsibility for corporate investor relations. Mr. Church joined Celsion in July 2010 as Vice President and Chief Financial Officer. Mr. Church brings more than 30 years of experience in corporate finance, mergers and acquisitions, investor relations, and SEC reporting. Prior to joining the Company, Mr. Church held senior financial executive positions with several private and public clinical stage Life Science companies including Alba Therapeutics Corporation, Novavax, Inc., GenVec, Inc., and Meridian Medical Technologies, Inc. Mr. Church started his career in 1979 with the public accounting firm, Price Waterhouse. Mr. Church holds a B.S. degree from the University of Maryland and received his Maryland Certified Public Accountant accreditation in 1979.
Executive Director, Strategic Planning & Business Development
Raj Prabhakar joined Celsion in January 2004 and served as Director of Program Management leading the liver cancer program from preclinical stage through launch of the Phase III HEAT Study. He was promoted to his current position of Executive Director of Strategic Planning & Business Development in January 2009, after serving as Senior Director of Strategic Planning and Business Development in December 2007. Mr. Prabhakar currently heads up out-licensing and business development activities for Celsion, including managing the collaboration relationship with Yakult Honsha Co., Ltd. for the Japan Territory. He has over 10 years of biomedical industry experience including Celsion (oncology), Protiveris (proteomics), Osiris Therapeutics (stem cells) and Harvard Medical School (orthopedic research). Prior to receiving his M.B.A., Raj held analyst positions for four years in several finance, venture capital and private equity firms. In addition to 15 years of experience, Raj holds an M.B.A. from the Harvard Business School and dual B.S. degrees from MIT in biology and mechanical engineering.
Robert A. Reed, PhD.
Vice President, CMC and Technical Operations
Robert A. Reed, Ph.D. joined Celsion in May 2009 as Executive Director, CMC and Technical Operations. In February 2011, Dr. Reed was promoted to Vice President, CMC and Technical Operations. In this position Dr. Reed oversees the manufacturing, QA and Technical Operations functions for Celsion. He most recently was Vice President, Pharmaceutical Operations at XenoPort, Inc., has over 20 years of experience and responsibility across XenoPort, Inc., Merck & Company, Inc., and The Liposome Company, Inc., with extensive scientific and regulatory experience in the design and development of pharmaceutical products. He holds a Ph.D. in Analytical Chemistry from The University of North Carolina at Chapel Hill and was the recipient of a 3 year NIH Postdoctoral Individual Award at Princeton University.